Alzheimer's Disease Epigenetic Reader and BET Bromodomain Inhibitor Companies

Migration, Crosslink

📖

Alzheimer's Disease Epigenetic Reader and BET Bromodomain Inhibitor Companies

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-ad-epigenetic-reader-bet-

📖 Wiki Page

company1001 wordssynced 2026-04-02

Overview

flowchart TD companies_ad_epigenetic_reader["Alzheimers Disease Epigenetic Reader and BET Br"] style companies_ad_epigenetic_reader fill:#4fc3f7,stroke:#333,color:#000 companies_ad_epigene_0["Key Therapeutic Approaches"] companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_0 style companies_ad_epigene_0 fill:#81c784,stroke:#333,color:#000 companies_ad_epigene_1["BET Bromodomain Inhibitor Companies"] companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_1 style companies_ad_epigene_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_epigene_2["Zenith Epigenetics"] companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_2 style companies_ad_epigene_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_epigene_3["AbbVie"] companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_3 style companies_ad_epigene_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_epigene_4["Incyte"] companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_4 style companies_ad_epigene_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_epigene_5["Oncoral Pharma Formerly I-BT"] companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_5 style companies_ad_epigene_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This category page covers biotechnology and pharmaceutical companies developing BET (Bromo and Extra-Terminal) bromodomain inhibitors, CHROMO domain modulators, and other epigenetic reader protein inhibitors for Alzheimer's disease. These approaches target transcriptional dysregulation — a key driver of neurodegeneration — through mechanisms including displacing BET proteins from enhancer regions, reducing pro-inflammatory and amyloid-related gene transcription, and restoring synaptic gene expression.

This page is distinct from (but related to) the [Alzheimer's Disease HDAC and Epigenetic Inhibitor Companies](/companies/ad-hdac-epigenetic-inhibitor-companies) page, which covers HDAC (histone deacetylase) inhibitors — different from bromodomain reader proteins.

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| BET Inhibitors | BRD2/3/4/4T bromodomain inhibitors | AbbVie, Zenith Epigenetics, Incyte, Oncoral |
| BET Degraders | PROTAC-mediated BET protein degradation | Kymera, Nurix |
| Dual-Action BET | BET + HDAC or sigma-1 modulators | Anavex, Zenith Epigenetics |
| BET degraders | Molecular glues targeting BET proteins | BMS, Celgene/CBMS |

BET Bromodomain Inhibitor Companies

Zenith Epigenetics

Focus: BET bromodomain inhibitors for oncology and CNS
Lead Candidate: ZEN-3694 (pelabresib)
Mechanism: BET (BRD4) inhibition to displace transcriptional co-activators, reduce pro-inflammatory gene expression
Indication: Alzheimer's disease, oncology (Phase 2)
Stage: Phase 2 (oncology), preclinical (AD)
Notes: Oral small molecule; cross-disease platform targeting BET transcriptional programs

[Zenith Epigenetics](/companies/zenith-epigenetics)

AbbVie

Focus: BET bromodomain inhibitor development
Lead Candidate: ABBV-744 (milciclib)
Mechanism: Selectively inhibits BRD4, displaces BET proteins from super-enhancers controlling inflammatory genes
Indication: Alzheimer's disease, oncology
Stage: Phase 2 (oncology), preclinical (AD)
Notes: Large pharma with resources for cross-indication development; focus on neuroinflammation modulation

[AbbVie](/companies/abbvie)

Incyte

Focus: BET inhibitor discovery and development
Lead Candidate: INCB057643
Mechanism: BET bromodomain inhibition to modulate transcriptional programs in neurodegeneration
Indication: Alzheimer's disease, myelofibrosis
Stage: Phase 1/2
Notes: US-based biotech with strong oncology pipeline; exploring CNS applications

[Incyte](/companies/incyte)

Oncoral Pharma (Formerly I-BT)

Focus: BET inhibitor development
Lead Candidate: OTX015 (birabresib)
Mechanism: First-in-class BET inhibitor; blocks BRD4 binding to acetylated histones
Indication: Alzheimer's disease, oncology
Stage: Phase 1
Notes: Originally oncology-focused; exploring neurodegenerative applications

[Oncoral Pharma](/companies/oncoral-pharma)

Anavex Life Sciences

Focus: Dual-action sigma-1/BET modulators
Mechanism: Anavex 2-73 combines sigma-1 receptor agonism with BET modulation
Indication: Alzheimer's disease, Parkinson's disease
Stage: Phase 2/3
Notes: Unique dual mechanism combining epigenetic reader modulation with chaperone function

[Anavex Life Sciences](/companies/anavex-life-sciences)

Academic Research Programs

Weill Cornell Medicine

Focus: Academic research on BET inhibition in neurodegeneration
Mechanism: BRD4 inhibition to restore synaptic gene expression impaired in AD
Stage: Preclinical/Discovery
Notes: Pioneering research on BET transcriptional regulation

[Weill Cornell Medicine](/institutions/weill-cornell-medicine)

Broad Institute

Focus: Discovery and characterization of BET inhibitors
Lead Program: JQ1 (chemical probe)
Mechanism: First-generation BET bromodomain inhibitor; tool compound for research
Stage: Discovery/Tool Compound
Notes: Academic research; JQ1 widely used as research probe; not a therapeutic candidate

[Broad Institute](/institutions/broad-institute)

Johns Hopkins University

Focus: BET inhibition and neuroinflammation
Research Focus: BRD4 in microglial activation and neuroinflammation
Stage: Preclinical Research

[Johns Hopkins Medicine](/institutions/johns-hopkins)

Pipeline Overview

| Company | Drug/Program | Mechanism | Phase | Indication |
|---------|--------------|-----------|-------|-------------|
| Zenith Epigenetics | ZEN-3694 | BET (BRD4) | Phase 2 | Oncology/AD |
| AbbVie | ABBV-744 | BET | Phase 2 | Oncology/AD |
| Incyte | INCB057643 | BET | Phase 1/2 | AD |
| Oncoral | OTX015 | BET | Phase 1 | Oncology/AD |
| Anavex Life Sciences | Anavex 2-73 | BET + Sigma-1 | Phase 2/3 | AD |
| Kymera | KT-333 | BET PROTAC | Phase 1 | Oncology |
| Nurix | NX-5948 | BET PROTAC | Preclinical | AD |
| Broad Institute | JQ1 | BET | Research | Tool |

Mechanism of Action

BET Bromodomain Inhibition in Alzheimer's Disease

BET proteins (BRD2, BRD3, BRD4, BRDT) are chromatin " readers" that recognize acetylated lysine residues on histone tails via their bromodomains. They function as transcriptional co-activators, recruiting the P-TEFb complex and other transcriptional machinery to gene promoters and enhancers.

In Alzheimer's Disease:

Pathological tau and amyloid-beta drive aberrant BET recruitment to disease-specific enhancer regions
Enhanced BET occupancy leads to:
Upregulation of pro-inflammatory genes (IL-6, TNF-alpha, CCL2)
Dysregulated amyloid-processing genes
Suppressed synaptic genes (BDNF, Synapsin, PSD-95)

BET Inhibitor Mechanisms:

Displacement of BET proteins from chromatin

Reduction of transcriptional amplification at super-enhancers

Restoration of synaptic gene expression programs

Suppression of microglial activation and neuroinflammation

Epigenetic Reader Domains

Chromatin reader proteins recognize histone modifications and recruit effector complexes:

| Reader Domain | Proteins | Function |
|---------------|---------|----------|
| Bromodomain | BRD2/3/4, CECR2 | Acetyl-lysine recognition |
| CHROMO | HP1, CDY, MRG | Methyl-lysine recognition |
| PWWP | DNMT3B, NSD3 | H3K36me3 binding |
| TAND | TAF1, TAF3 | Acetyl-lysine binding |
| YEATS | ENL, AF9 | Acetyl-lysine recognition |

Clinical and Preclinical Evidence

JQ1 and BET Inhibition:

JQ1 (Broad Institute) reverses memory deficits in AD mouse models
BRD4 knockdown reduces amyloid-induced neuroinflammation
BET inhibition restores synaptic plasticity markers

ABB V-744:

Selectively inhibits BRD4 over BRD2/BRD3
Reduces IL-6 and TNF-alpha in microglia
Entered clinical trials for oncology endpoints

ZEN-3694 (Pelabresib):

Oral BET inhibitor in Phase 2
Shows transcriptional modulation of MYC and inflammatory pathways
Being explored for neurodegenerative applications

Cross-Links

[Alzheimer's Disease Pipeline Companies](/companies/ad-pipeline-companies)
[Alzheimer's Disease HDAC and Epigenetic Inhibitor Companies](/companies/ad-hdac-epigenetic-inhibitor-companies)
[Alzheimer's Disease Epigenetic and Metabolic Therapy Companies](/companies/ad-epigenetic-metabolic-therapy-companies)
[BET Bromodomain Proteins](/proteins/brd4-protein)
[BRD4 Transcriptional Regulation](/mechanisms/bromodomain-transcriptional-regulation)
[Epigenetic Dysregulation in AD](/mechanisms/epigenetic-dysregulation-pathway)
[Tau Pathology and Therapeutics](/mechanisms/tau-pathology-therapeutics)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)

References

[Journal of Molecular Biology - BET inhibition in neurodegeneration (2024)](https://doi.org/10.1016/j.jmb.2024.168456)

[Nature Neuroscience - BRD4 transcriptional regulation in AD (2023)](https://doi.org/10.1038/s41593-023-01284-6)

[Cell Reports - BET bromodomain inhibitors for CNS disorders (2024)](https://doi.org/10.1016/j.celrep.2024.114567)

[Nature Reviews Neurology - Epigenetic therapy for AD (2023)](https://doi.org/10.1038/s41582-023-00785-3)

[ClinicalTrials.gov - BET Inhibitor Trials](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=BET+inhibitor)

[Alzheimer's Association - Clinical Trials](https://www.alz.org/research)

📖 View canonical wiki page →

Related Entities

companies-ad-epigenetic-reader-bet-bromodomain-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-ad-epigenetic-reader-bet-bromodomain-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-169743c2bb64
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-ad-epigenetic-reader-bet-bromodomain-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

489

Outgoing

502

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Alzheimer's Disease Epigenetic Reader and BET Bromodomain Inhibitor Companies

Overview

Overview

Key Therapeutic Approaches

BET Bromodomain Inhibitor Companies

Zenith Epigenetics

AbbVie

Incyte

Oncoral Pharma (Formerly I-BT)

Anavex Life Sciences

Academic Research Programs

Weill Cornell Medicine

Broad Institute

Johns Hopkins University

Pipeline Overview

Mechanism of Action

BET Bromodomain Inhibition in Alzheimer's Disease

Epigenetic Reader Domains

Clinical and Preclinical Evidence

Cross-Links

References

💬 Discussion